Monitoring sedation depth with brain wave monitors during emergency procedures

ISRCTN ISRCTN55036065
DOI https://doi.org/10.1186/ISRCTN55036065
Sponsor Atatürk University
Funder Investigator initiated and funded
Submission date
06/10/2026
Registration date
06/10/2026
Last edited
06/10/2026
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Surgery
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Mr Furkan Akpinar
Public, Scientific, Principal investigator

Hüseyin Avni Ulaş Neighborhood, Necip Fazıl Kısakürek Boulevard, C2-35 Block, No: 1-3G/15
Yıldızkent 1st Stage TOKİ Housing
Erzurum
25080
Türkiye

ORCiD logoORCID ID 0009-0007-2089-5437
Phone +90 05400750001
Email furkan.akpinar1@saglik.gov.tr

Study information

Primary study designInterventional
AllocationRandomized controlled trial
MaskingBlinded (masking used)
ControlActive
AssignmentParallel
PurposeDevice feasibility, Supportive care, Treatment
Scientific titleAssessment of procedural sedation depth with bispectral ındex in the emergency department: a randomized controlled, double-blind study
Study objectives
Ethics approval(s)

Approved 27/01/2022, Ataturk University Faculty of Medicine Clinical Research Ethics Committee (Ataturk Mah., Ataturk University Campus, Yakutiye, Erzurum, 25240, Türkiye; +90 (0)442 234 65 11; atatipetikkurul@gmail.com), ref: B.30.2.ATA.0.01.00/97

Health condition(s) or problem(s) studiedProcedural sedation and analgesia in adult emergency department patients requiring procedural sedation for painful interventions.
InterventionEligible participants presenting to the emergency department who require procedural sedation and analgesia (PSA) are randomly allocated to one of two parallel groups using sealed, sequentially numbered envelopes:
1. Propofol-Fentanyl Group (Group 1): Participants receive intravenous (IV) propofol (maximum 1 mg/kg) combined with IV fentanyl (1 mcg/kg)
2. Propofol-Midazolam Group (Group 2 - Active Control): Participants receive intravenous (IV) propofol (maximum 1 mg/kg) combined with IV midazolam (0.05 mg/kg)

To ensure blinding, study medications are prepared in identical sealed syringes by an independent provider. Half of the total calculated dose is administered as an initial IV bolus, followed by gradual titration at 2–3-minute intervals if target moderate sedation is not achieved, without exceeding the predetermined maximum dose limit.

Before drug administration, single-use Bispectral Index Monitor (BIS; Aspect BIS Vista monitor / Aspect Medical Systems / Covidien-Medtronic) electrodes are placed on the forehead, and non-invasive hemodynamic monitoring (blood pressure, heart rate, pulse oximetry, and respiratory rate) is initiated. Baseline (minute 0) BIS and vital parameters are recorded. During the reduction procedure, BIS values, clinical sedation depth (assessed via verbal and tactile stimuli by a blinded observer), and vital signs are recorded minute by minute. Monitoring continues until participants return to their baseline cognitive levels (standardized as a BIS score ≥ 90 and return of orientation).
Intervention typeDrug/Device
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Propofol (propofol), fentanyl (fentanyl citrate), midazolam (midazolam hydrochloride), bispectral index monitor
Primary outcome measure(s)
  1. Depth of procedural sedation measured using bispectral Index (BIS) monitoring (Aspect BIS Vista monitor) at minute-by-minute timepoints from the procedure start (minute 0) until the end of procedure, and minimum BIS value recorded during the procedure
Key secondary outcome measure(s)
Completion date01/01/2023

Eligibility

Participant type(s)
Age groupMixed
Lower age limit18 Years
Upper age limit65 Years
SexAll
Target sample size at registration90
Total final enrolment91
Key inclusion criteria1. Patients aged between 18 and 65 years
2. Presenting to the emergency department and requiring procedural sedation and analgesia (PSA) for closed reduction of extremity fractures or dislocations
3. Able to read, understand, and write in Turkish
4. American Society of Anesthesiologists (ASA) Physical Status Class I or Class II
5. Provision of written informed consent by the patient
Key exclusion criteria1. Patients younger than 18 or older than 65 years of age
2. Known allergy or hypersensitivity to any of the study medications (propofol, fentanyl, or midazolam)
3. American Society of Anesthesiologists (ASA) Physical Status Class ≥ 3 or ASA Class E according to ICAPS criteria
4. Uncontrolled diabetes mellitus, uncontrolled hypertension, or serious underlying cardiac or chronic pulmonary disease
5. Identified risk for difficult airway or high risk for pulmonary aspiration
6. Pregnancy or breastfeeding
7. Indications requiring minimal/dissociative sedation only or general anesthesia
8. Pre-existing cognitive dysfunction or inability to give informed consent
9. Impaired skin integrity in the frontal/forehead region preventing BIS sensor placement
Date of first enrolment01/02/2022
Date of final enrolment07/11/2022

Locations

Countries of recruitment

  • Türkiye

Study participating centres

Results and Publications

Individual participant data (IPD) Intention to shareNo

Editorial Notes

06/10/2026: Study's existence confirmed by the Ataturk University Faculty of Medicine Clinical Research Ethics Committee.